Drug Profile
Research programme: anti-CD4 molecules - Adeona Pharmaceuticals
Latest Information Update: 06 May 2011
Price :
$50
*
At a glance
- Originator Thomas Jefferson University
- Developer Adeona Pharmaceuticals
- Class Cyclic peptides; Small molecules
- Mechanism of Action CD4 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Immunological disorders
Most Recent Events
- 31 Mar 2011 Discontinued for Immunological disorders in USA (PO)
- 28 Feb 2008 Early research in Immunological disorders in USA (unspecified route)